Cancer Clinical Trial Eligibility: What Qualifies You to Enroll

August 23, 2026

Cancer Clinical Trial Eligibility: What Qualifies You to Enroll

Hands placing blood samples on lab bench

Eligibility for a cancer clinical trial comes down to six moving parts: your cancer type and stage, biomarker or genetic profile, performance status, lab values, prior treatments, and organ function alongside any current medications. None of these disqualify you automatically. The single best next step is to pull the trial’s protocol synopsis and call the trial coordinator for pre-screening before you assume you don’t qualify. Federal guidance is actively pushing trials toward broader inclusion, not narrower gatekeeping, so a criterion that would have excluded you five years ago may no longer apply.

Before you dig into any specific trial listing, keep these in mind:

Your diagnosis details (type, stage, biomarkers) get compared against the protocol’s inclusion list first.
Performance status and labs are evaluated with some clinical judgment, not just a rigid cutoff.
Prior treatments and current medications matter mostly when they could interfere with the study drug or mask results.
A “no” from a screening call is often a “not yet” or “not for this trial” rather than a permanent exclusion.

Key Takeaways

Cancer trial eligibility depends on matching your diagnosis, performance status, labs, and treatment history against a protocol that regulators are actively pushing to make more inclusive.

Point	Details
Start with the coordinator	Call the trial’s coordinator for pre-screening before assuming a criterion disqualifies you.
Performance status is shifting	FDA’s July 2026 guidance encourages including ECOG 2 patients when safety data support it.
Labs allow clinical judgment	Borderline values may still qualify if local lab ranges or repeat testing support eligibility.
Washouts are becoming recovery based	Guidance favors documented recovery from toxicity over arbitrary waiting periods.
Document everything	A treatment timeline, current labs, and medication list speed up accurate screening.

What Inclusion and Exclusion Criteria Actually Mean
Performance Status: The ECOG and Karnofsky Scales Explained
Which Lab Values Determine Whether You Qualify?
How Prior Treatments and Washout Periods Affect Eligibility
Do Brain Metastases Automatically Rule You Out?
Organ Function, Chronic Conditions, and Age: Where the Rules Are Loosening
How Do You Check Eligibility and Start Screening?
What Do FDA, NCI, and ASCO Guidance Actually Say About Broadening Eligibility?
Screening Tips That Prevent Avoidable Rejections
How HCRF Helps Patients Navigate Eligibility Questions
Our Take: Eligibility Rules Are Loosening Faster Than Common Advice Suggests
Sources

What Inclusion and Exclusion Criteria Actually Mean

Inclusion criteria are the traits a trial requires you to have. Exclusion criteria are the traits that keep you out. A lung cancer trial testing a targeted therapy might require an EGFR mutation (inclusion) while excluding anyone with untreated brain metastases (exclusion). A trial for newly diagnosed patients might require you to be treatment naive (inclusion) while excluding anyone who received a specific class of chemotherapy in the past six months (exclusion).

These rules exist for two reasons: safety and scientific validity. A trial testing a drug metabolized by the liver will exclude patients with severe liver impairment because the drug could accumulate to dangerous levels. A trial testing whether a new immunotherapy improves survival will often require a fairly uniform patient population at the start, so researchers can tell whether the drug caused the outcome rather than some other variable.

That second reason is exactly what regulators are now pushing back on. According to NCI’s guidance for finding a trial, eligibility criteria specifically list cancer type and stage, prior treatment history, tumor genetic changes, age, medical history, and current health status, and you’re expected to compare your own records against that list before contacting the coordinator.

The policy shift worth remembering: exclusions increasingly need a scientific justification, not just tradition. A criterion that was copied from an older trial without re-examination is precisely the kind of rule current guidance wants removed.

Performance Status: The ECOG and Karnofsky Scales Explained

Performance status measures how well you function day to day, and it’s one of the most consistently applied eligibility filters across cancer trials. The Eastern Cooperative Oncology Group (ECOG) scale runs from 0 to 5:

ECOG 0: Fully active, no restrictions.
ECOG 1: Restricted in strenuous activity but able to do light work.
ECOG 2: Ambulatory and capable of self-care but unable to work; up and about more than half of waking hours.
ECOG 3: Limited self-care; confined to bed or chair more than half of waking hours.
ECOG 4: Completely disabled, no self-care, fully confined.

Karnofsky scoring runs 0 to 100 in ten-point increments and maps roughly to the same functional bands. Most trials historically required ECOG 0 or 1, which quietly excluded many real-world cancer patients who are sicker than a typical trial participant.

That’s changing. FDA’s July 2026 draft guidance on performance status recommends broadening eligibility to include ECOG 2 patients when safety data support it, using prespecified cohorts if needed to track outcomes separately. The goal is a trial population that actually resembles the patients who will use the drug once it’s approved.

Pro Tip: Ask your oncologist to document your performance status in your chart before you approach a trial coordinator. A dated ECOG or Karnofsky assessment from your treating physician carries more weight than a self-reported estimate during a phone screen.

Which Lab Values Determine Whether You Qualify?

Most protocols set thresholds for a standard panel: complete blood count with absolute neutrophil count, platelets, liver enzymes (AST/ALT), bilirubin, and kidney function via creatinine or estimated glomerular filtration rate (eGFR). These numbers matter because a drug that’s cleared through the liver or kidneys can become toxic if those organs aren’t functioning well enough to process it.

The catch is that older trials often set arbitrary cutoffs without much clinical rationale. Current guidance pushes back on that. Regulatory recommendations increasingly favor clinical judgment over rigid numeric walls, including acceptance of local lab reference ranges rather than forcing every site to a single central-lab standard, according to FDA guidance on eligibility criteria for laboratory values.

If your labs land just outside a stated range:

Bring your most recent full panel, even if it’s not from the trial site.
Ask whether a repeat test closer to screening might land you back in range.
Ask directly whether the protocol accepts your local lab’s normal range instead of the sponsor’s default cutoff.

A single borderline creatinine value shouldn’t end the conversation before it starts.

How Prior Treatments and Washout Periods Affect Eligibility

Prior therapy history cuts both ways. Some trials require you to have failed a specific treatment first, since testing a new drug on treatment-naive patients wouldn’t answer the question the study is designed to answer. Other trials exclude anyone who’s had certain prior therapies because residual drug effects could interfere with measuring the new treatment’s safety or efficacy.

Hands writing treatment timeline on chart

Washout periods, the mandatory waiting time between your last treatment and trial enrollment, exist to let earlier drugs clear your system. But fixed time windows (say, “four weeks since last chemotherapy”) are increasingly seen as a blunt instrument. Guidance from ASCO, Friends of Cancer Research, and the National Cancer Institute’s clinical trials program recommends replacing arbitrary time-based washouts with recovery-based criteria: has the toxicity actually resolved, regardless of how many days have passed? The same CTEP eligibility modernization guidance extends this thinking to prior-therapy restrictions generally.

That matters because restrictive prior-therapy rules can produce a trial population that looks nothing like real-world patients, according to a peer-reviewed analysis from the ASCO–Friends of Cancer Research working group, which found that minimizing unnecessary restrictions tends to improve both enrollment and representativeness.

Pro Tip: Build a one-page treatment timeline before you call any trial coordinator. List every regimen, start and stop dates, doses, and how you tolerated each one. It turns a vague conversation into a fast, factual eligibility review.

Do Brain Metastases Automatically Rule You Out?

Not anymore, in most cases. Trials distinguish sharply between treated, stable brain metastases and active or progressing disease. If your brain metastases have been treated with surgery or radiation and show no progression on imaging for a defined period, usually several weeks to a few months depending on the protocol, you’re commonly eligible. Active, untreated brain metastases or leptomeningeal disease (cancer spread to the fluid surrounding the brain and spinal cord) remain more restrictive categories, though even here inclusion is expanding.

Guidance from ASCO, Friends of Cancer Research, and NCI specifically calls out brain metastases as an area where many previously excluded patients should now be considered, provided their disease is stable.

To move screening along quickly:

Bring your most recent brain MRI or CT, not an older scan.
Include the radiation oncology or neurosurgery note confirming treatment and stability.
Note any steroid taper history, since some protocols require a stable or minimal steroid dose at enrollment.

Organ Function, Chronic Conditions, and Age: Where the Rules Are Loosening

Trials assess liver enzymes, kidney function, and cardiac tests (often an echocardiogram or EKG for drugs with known heart risks) because these systems determine how a drug is processed and how much risk you’re taking on. That part hasn’t changed. What has changed is how sponsors treat patients with chronic, controlled conditions.

Stethoscope and blood pressure cuff on desk

Patients with well-controlled HIV, treated hepatitis B or C, or other stable chronic diseases were routinely excluded from trials for decades on the theory that their condition might confound results. Evidence now shows that a controlled chronic condition doesn’t automatically compromise safety or efficacy data, and protocols increasingly allow enrollment when the condition isn’t expected to interfere with the study’s endpoints, according to research reviewing inclusivity for chronic conditions.

Some sponsors now use pharmacokinetic modeling or prespecified cohorts to include patients with mild to moderate organ dysfunction, tracking their outcomes separately rather than excluding them outright. If your chart shows a well-managed chronic condition, ask the trial coordinator directly whether the protocol has a cohort or modeling pathway for patients like you rather than assuming a blanket exclusion applies.

How Do You Check Eligibility and Start Screening?

Moving from “I think I might qualify” to a formal screening visit follows a fairly consistent sequence, whether you’re doing this yourself or with a caregiver’s help.

Gather your records first. Pull your pathology report, staging documentation, any biomarker or genetic test results, a full treatment timeline with dates and doses, labs from the past four to six weeks, your current medication list (including supplements), and a note on your performance status.
Search for trials using primary sources. Start with Clinicaltrials or the NCI’s trial search tool. Read the protocol synopsis closely; it lists the core inclusion and exclusion criteria in plain language before you ever speak to anyone.
Call the trial coordinator, not the principal investigator. The coordinator handles preliminary screening and can tell you within minutes whether obvious disqualifiers apply, per NCI’s guidance on finding a clinical trial.
Expect a pre-screen phone or records review, followed by formal screening if you pass the first pass. Formal screening usually involves new baseline labs, imaging, and sometimes a physical exam, even if you look like a match on paper.
Ask about exceptions or waivers explicitly. If one lab value or one criterion is borderline, ask whether the protocol allows a documented exception rather than assuming a hard stop.

Pro Tip: Don’t wait for a scan to be “due” before pursuing trial screening. Formal eligibility review can take one to three weeks, and some trials have enrollment caps by biomarker subgroup that fill faster than you’d expect.

For biomarker-specific searches, a resource like RareLabs’ knowledge base can help you locate trials organized around rare mutations or subtypes that general search tools sometimes bury.

What Do FDA, NCI, and ASCO Guidance Actually Say About Broadening Eligibility?

Three streams of guidance are converging on the same message: cancer trials have been excluding patients for reasons that don’t hold up scientifically, and that needs to change. The FDA’s July 2026 draft guidance targets performance status directly, recommending inclusion of ECOG 2 patients when safety allows. A companion FDA guidance document addresses lab values and washout periods, pushing sponsors toward clinically justified recovery criteria instead of arbitrary time windows.

The ASCO, Friends of Cancer Research, and NCI joint guidance goes further, covering brain metastases, minimum age thresholds, HIV/HBV/HCV status, and prior-therapy restrictions as areas ripe for modernization.

Modernizing eligibility criteria is meant to shrink the gap between trial populations and the patients oncologists actually treat, reducing unnecessary exclusions that slow enrollment and limit what a trial’s results can tell us.

For patients, this means asking your care team a sharper question than “am I eligible?” Ask instead: “Has this trial adopted the newer, broader criteria for [performance status / brain mets / prior therapy], or is it still using the older standard?” That single question can surface flexibility a coordinator won’t volunteer unprompted.

Screening Tips That Prevent Avoidable Rejections

Most avoidable exclusions come down to paperwork, not medicine. Ask for the trial coordinator by name during your first call, since they run pre-screening and know the protocol’s real-world flexibility better than a general intake line. Bring labs and imaging that are current, not from three months ago, and hand over a treatment timeline that’s complete rather than summarized from memory.

Common pitfalls worth avoiding:

Submitting outdated labs that force a repeat visit before screening can even begin.
Leaving supplements, over-the-counter drugs, or herbal products off your medication list.
Failing to document that you’ve fully recovered from a prior treatment’s side effects, which can trigger an unnecessary washout delay.

If you’re told no, ask specifically about a waiver request, an expanded access pathway, or a referral to a sister trial site running the same protocol with different site-level thresholds.

Pro Tip: Keep a single folder, digital or physical, with every document a coordinator might ask for. Patients who show up organized to a screening call routinely move through pre-screening faster than those who promise to "send it over later.

How HCRF Helps Patients Navigate Eligibility Questions

The Hippocratic Cancer Research Foundation funds innovative cancer research at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, and part of that mission includes helping patients understand what trial participation actually involves. HCRF’s patient guides, including resources on immunotherapy clinical trials and informed consent in clinical trials, walk through exactly the kind of documentation and questions this article covers.

A few ways these resources help in practice:

They explain biomarker testing in plain language, which helps you interpret molecular eligibility criteria before you speak with a coordinator.
They break down the informed consent process, so you know what you’re agreeing to before formal screening begins.
They point to practical considerations, like insurance coverage during a trial, that eligibility discussions often skip entirely.

Every dollar donated to HCRF goes toward funding the kind of research that keeps pushing trial eligibility, and treatment options, forward for patients who might otherwise have run out of paths.

If this article helped clarify what’s possible, HCRF depends on donor support to keep funding the research that broadens who gets a shot at these trials in the first place. A gift today helps make the next generation of cancer treatment accessible to the patients who need it most.

Our Take: Eligibility Rules Are Loosening Faster Than Common Advice Suggests

Most patient advice on trial eligibility still reads like it was written for the old rulebook: assume rigid cutoffs, assume brain metastases mean automatic exclusion, assume a washout period is fixed and non-negotiable. That advice is going stale in real time. The FDA’s own 2026 guidance and the ASCO–Friends–NCI modernization work make clear that regulators see the old restrictive model as a scientific liability, not a safety necessity.

What the evidence actually supports is a more assertive patient posture. Don’t self-select out of a trial based on a criterion you read online. Get your documentation in order, treatment timeline, current labs, performance status note, and let a coordinator make the actual determination against the current protocol. The gap between what patients assume disqualifies them and what actually does is often wider than expected.

Where conventional advice falls short is treating eligibility as static. It isn’t. Ask explicitly whether a trial has adopted broader criteria before accepting a first “no.”

This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.

News